MedTrace Logo

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

NCT03874897 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2024-04-30

No results posted yet for this study

Summary

An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

CAR-CLDN18.2 T-Cells

Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses • Chimeric Antigen Receptor T Cells Targeting Claudin18.2

DRUG

PD-1 Monoclonal Antibody

Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1

DRUG

Chemotherapy

First-line systemic therapy according to physician's choice

Sponsors & Collaborators

  • CARsgen Therapeutics Co., Ltd.

    collaborator INDUSTRY

  • Peking University

    lead OTHER

Principal Investigators

  • Lin Shen · Peking University Cancer Hospital & Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-26
Primary Completion
2021-03-20
Completion
2024-01-26

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03874897 on ClinicalTrials.gov